Seliciclib (CYC202 or r-roscovitine) is novel cell cycle drug belonging to the Cyclin Dependent Kinase
(CDK) inhibitor class.
Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase
Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines" (Abstract # 971)
Over-stimulation of ErbB receptors results in the increased production of cyclin D1, a signaling molecule that activates cyclin dependent kinases
(CDKs), resulting in tumor cell proliferation.
SNS-032 is a novel cyclin dependent kinase
(CDK) inhibitor that induces cell-cycle arrest and apoptosis.
In April at the Annual Meeting of the American Association for Cancer Research Cyclacel reported preclinical results from a combination study of seliciclib, an orally-available cyclin dependent kinase
(CDK) inhibitor, with epidermal growth factor receptor (EGFR) inhibitor drugs, including erlotinib (Tarceva[R]).
In addition, data on AZD5438, a selective cyclin dependent kinase
inhibitor in phase I development; ZD6126, a vascular targeting agent; and two compounds in the pre-clinical development stage, AZD6244 (MEK inhibitor) and AZD1152 (an aurora kinase inhibitor), will be presented during the meeting.
R-Roscovitine (CYC202), a Cyclin Dependent Kinase
(CDK) Inhibitor, Reduces Autoimmune Renal Injury and Prolongs Life in Murine Lupus Nephritis.
Abstract Number: C81 Schedule dependency of combining CYC202 (R- Roscovitine), a cyclin dependent kinase
inhibitor, with docetaxel in human tumor xenografts in vivo.
CYC202 (R-roscovitine) is a small molecule inhibitor of Cyclin Dependent Kinase
2 (CDK2), an enzyme target of the body's own anticancer genes, such as the tumour suppressor p21.
The p16 and p27 cell cycle inhibitor genes, also referred to as cyclin dependent kinase
inhibitors (CDKi), play a key role in the natural regulation of cellular division.